



# Donor Pool SIZE MATTERS for Allogeneic Cell Therapies



You know sourcing your starting material from healthy, high quality donors matters when you are manufacturing an allogeneic cell therapy. But the size of the donor pool can also impact your therapy's success.

**How?** Donor pool depth can impact the likelihood of sourcing donors who meet all eligibility requirements. And as your therapy scales from early clinical trials to commercialization, your cell sourcing partner must have a large enough donor pool to scale with you.

To identify a sufficient number of donors who meet study eligibility, health authority and medical suitability requirements, a large donor pool is required even for the most common HLA genotypes. As the HLA genotype frequency decreases, the initial donor pool must increase. Additionally, geographic restriction of a donor pool can further limit diversity, requiring an even larger starting pool of donors.



## YOU MUST HAVE A MINIMUM DONOR POOLS SIZE OF

	MOST COMMON GENOTYPE	25TH MOST COMMON GENOTYPE	50TH MOST COMMON GENOTYPE	
	4,302	24,057	37,133	CAUCASIAN
	7,957	486,670	611,041	HISPANIC OR LATINO
	83,072	158,483	410,401	ASIAN-PACIFIC ISLANDER
	187,053	9,848	15,632	AFRICAN AMERICAN

Consider this example looking for only



**10 QUALIFIED MATCHED DONORS**  
for the most common HLA genotypes.<sup>1,2,3,4,5</sup>

\*The total number of **DISTINCT GENOTYPES** in each broad race group were:

Caucasian	1.15 million genotypes
Hispanic or Latino	462,000 genotypes
Asian-Pacific Islander	382,000 genotypes
African American	365,000 genotypes

### Donor pool depth does matter.

Choose a partner whose registry size and diversity are built to scale with you.

### When you are selecting a cell sourcing partner for your allogeneic cell therapy, ask:

- How many donors are on your registry?
- What is the diversity of your registry?
- How often do you rely on your donors for repeat donations?

# Support for your allogeneic therapy



NMDP BioTherapies<sup>SM</sup> offers the donor pool and cell sourcing expertise you need to reliably identify, collect and deliver allogeneic volunteer donor cellular starting material that meets your requirements.

Backed by decades of experience, our immunogenetics and bioinformatics professionals have the data and analytical expertise to identify the most compatible source material from NMDP Registry<sup>SM</sup>.

Discover how our customized solutions can help you minimize your risk and consistently access allogeneic source material you can count on.

**nmdpbiotherapies.com**  
**info@nmdpbiotherapies.com**  
**1 (800) 471-4431**

1. Data is based on a segment of approximately 4.5 million U.S.-based potential donors from the volunteer NMDP Registry. All figures assume 100% donor willingness to participate in collection for a cell or gene therapy.
2. Race group determinations are self-reported by potential donors at the time they join the registry.
3. Genotype frequency is based on donor frequency on the Be The Match Registry and may not mirror overall population genetics.
4. Ineligibility percentages are averages based on multiple studies currently in progress and may change based on region and therapy-specific requirements.
5. This count includes NMDP Registry members who did not identify as the particular race group, but have the required genotype. This accounts for the reduced donor pool size at the less common genotypes within the African American group.